Qiagen and WuXi AppTec Partner for Molecular Biomarkers

Qiagen (Shanghai, China) announced a partnership to provide an integrated single solution for molecular biomarker development, validation, and personalized healthcare targets.

Under the terms of the partnership agreement, WuXi AppTec (Shanghai, China) will work with Qiagen to develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that Qiagen intends to bring to market.

Qiagen will provide a complete portfolio of instrumentation, training, and consumables; WuXi AppTec will supply laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately.

WuXi AppTec will use technologies for a broad range of applications in support of diagnostics development and drug discovery on behalf of the company's and Qiagen's customers. Qiagen's sample and assay technologies are an integral part of research and development (R&D) laboratories throughout the world. By supplying disease- and pathway-focused panels, the company catalyzes the development of novel molecular diagnostic assays and contributes to the discovery and validation engines of biomedical and pharmaceutical institutions.

Qiagen's Asia headquarters are housed in Shanghai's Zhangjiang high-technology park, a major research and development hub in China. Qiagen Asia also maintains offices in Korea, Malaysia, Singapore, and India. The company's Asian operations, together with the Japanese subsidiary, contribute approximately 13% to its overall net sales.

In 2006, Qiagen received the Frost & Sullivan award for Competitive Strategy Leadership in recognition of strategic initiatives in the Asia Pacific molecular testing market.

Related Links:
Qiagen
WuXi AppTec